0001209191-13-032020.txt : 20130613 0001209191-13-032020.hdr.sgml : 20130613 20130613155210 ACCESSION NUMBER: 0001209191-13-032020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130612 FILED AS OF DATE: 20130613 DATE AS OF CHANGE: 20130613 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 100 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 100 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EVNIN LUKE CENTRAL INDEX KEY: 0001134657 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 13911463 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 54TH STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-06-12 0 0001396814 Pacira Pharmaceuticals, Inc. PCRX 0001134657 EVNIN LUKE C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 2013-06-12 4 S 0 2435 30.00 D 20311 D Common Stock 2013-06-13 4 S 0 20311 30.0745 D 0 D Common Stock 824255 I See Footnote Director Stock Option (Right to Buy) 29.90 2013-06-12 4 A 0 7000 0.00 A 2023-06-12 Common Stock 7000 7000 D This transaction was pursuant to a 10b5-1 Plan. Represents the average sales price. The shares were sold between $30.00 and $30.38. The Reporting Person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price. The shares are held as follows: 772,568 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 29,769 by by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 21,918 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The option vests in twelve equal monthly installments following the vesting commencement date of June 12, 2013. /s/ Luke Evnin 2013-06-13